Meeting
2022 ASCO Annual Meeting
Efficacy and safety of camrelizumab and apatinib combined with induction chemotherapy and concurrent chemoradiotherapy for stage TanyN3M0 nasopharyngeal carcinoma: A phase II QUINTUPLED trial.
Authors
Hu Liang
Department of Nasopharyngeal Carcinoma, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China
Hu Liang , Lin Wang , Nian Lu , Yao-Fei Jiang , Jian-Wei Wang , Wei-Xin Bei , Liang-Ru Ke , Yan-Fang Ye , Guo-Ying Liu , Wang-Zhong Li , LiTing Liu , Jin-Ling Duan , Chong Zhao , Weixiong Xia , Xiang Yanqun
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
ChiCTR2000032317
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 6012)
DOI
10.1200/JCO.2022.40.16_suppl.6012
Abstract #
6012
Poster Bd #
4
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Efficacy and safety of camrelizumab combined with apatinib in previously treated recurrent or metastatic nasopharyngeal carcinoma: A phase II clinical trial.
First Author: Lin-Quan Tang
Poster
2024 ASCO Breakthrough
Efficacy and safety analysis on the combination of camrelizumab with nab-paclitaxel and cisplatin-based chemotherapy in first-line treatment of advanced or metastatic esophageal squamous cell carcinoma.
First Author: Xiaofeng Cong
Poster
2023 ASCO Annual Meeting
Efficacy and safety of camrelizumab in combination with radiation and chemotherapy for recurrent or metastatic cervical cancer.
First Author: Zhongjie Chen
Poster
2023 ASCO Annual Meeting
A multicenter phase I/II trial of induction chemotherapy followed by camrelizumab, apatinib, plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer.
First Author: Chengzhi Zhou